LIPAC Oncology focuses on innovative drug delivery systems designed to enhance the treatment of cancer. Their proprietary technology utilizes a unique formulation that allows for localized delivery of therapeutic agents directly to tumors, minimizing systemic exposure and potential side effects. This targeted approach aims to improve the efficacy of cancer treatments while reducing the burden on patients, making therapies more tolerable and effective.

The company’s pipeline includes a range of products that leverage this advanced drug delivery mechanism, showcasing their commitment to developing novel therapies for various types of cancer. By integrating cutting-edge science with practical applications, LIPAC Oncology is positioned to address significant unmet medical needs in oncology, offering hope for improved outcomes in cancer care through their specialized technologies.

United States

LIPAC Oncology is a pharmaceutical company focused on advancing the development of new investigational therapies to treat intracavitary cancers. Its precision targeted liposome-bound nano-technology platform provides local delivery of taxane for the treatment of multiple tumor types. LiPax, its lead investigational candidate for the treatment of non-muscle invasive bladder cancer, is in Phase 2b development. The Company's pipeline includes multiple orphan indications such as upper tract urothelial carcinoma, stage II/III ovarian cancer and mesothelioma.

LIPAC Oncology

Company Details